![Philip Astley-Sparke](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Philip Astley-Sparke
Founder at
REPLIMUNE GROUP, INC.
Net worth: 12 M $ as of 2026-05-30
Profile
Philip Astley-Sparke is the founder of Replimune Group, Inc., founded in 2015, where the title held is Executive Chairman since 2024.
Mr. Astley-Sparke was the founder of Replimune Ltd., founded in 2015, where the title held was Director from 2015 to 2024.
Current jobs include Independent Director at enGene Therapeutics, Inc. starting in 2025 and Operating Partner at Forbion Capital Partners Management Holding BV since 2012.
Former jobs include President & Chief Executive Officer at BioVex, Inc. from 2000 to 2011; President & Chief Executive Officer at BioVex Group, Inc.; Chairman at uniQure NV from 2016 to 2021; Chairman at Oxyrane, Ltd. from 2012 to 2020; Independent Non-Executive Director at Forbion European Acquisition Corp.; Vice President & General Manager at Amgen, Inc.; President at uniQure, Inc. from 2013 to 2015; and Accountant at Arthur Andersen LLP.
Education includes undergraduate degree from the University of Bristol.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-05-17 | 1,412,414 ( 1.81% ) | 12 M $ | 2026-05-30 | |
| 2026-06-15 | 20,000 ( 0.03% ) | 37 000 $ | 2026-05-30 |
Philip Astley-Sparke active positions
| Companies | Position | Start |
|---|---|---|
| REPLIMUNE GROUP, INC. | Founder | 2015-02-28 |
| ENGENE THERAPEUTICS INC. | Director/Board Member | 2025-07-07 |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion is an active manager invest companies located in Northwest Europe and the United States. The firm focuses on companies operating in the fields of life sciences and biomedical technology. It participates in early stage capital requirements with an investment size ranging from EUR 1 - 7 million. It participates in follow-on investments, takes a board seat and acts as lead investor. | Private Equity Investor | 2012-04-30 |
Former positions of Philip Astley-Sparke
| Companies | Position | End |
|---|---|---|
Replimune Ltd.
 Replimune Ltd. Miscellaneous Commercial ServicesCommercial Services Research and develops cancer therapeutics | Founder | 2024-10-03 |
| UNIQURE N.V. | Chairman | 2021-06-14 |
Oxyrane, Ltd. | Chairman | 2019-12-31 |
uniQure, Inc.
 uniQure, Inc. BiotechnologyHealth Technology Provides research and development services of human gene based therapies | President | 2015-01-31 |
| AMGEN INC. | Corporate Officer/Principal | 2011-11-30 |
Training of Philip Astley-Sparke
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
52
1st degree connections
13
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 13 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology Develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases | Health Technology |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology Develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases | Health Technology |
Arthur Andersen LLP
 Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Provides accounting services | Commercial Services |
University of Bristol
 University of Bristol Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion is an active manager invest companies located in Northwest Europe and the United States. The firm focuses on companies operating in the fields of life sciences and biomedical technology. It participates in early stage capital requirements with an investment size ranging from EUR 1 - 7 million. It participates in follow-on investments, takes a board seat and acts as lead investor. | Finance |
uniQure NV
 uniQure NV BiotechnologyHealth Technology Engages in the discovery, development and commercialization of gene therapies products | Health Technology |
uniQure, Inc.
uniQure, Inc. BiotechnologyHealth Technology Provides research and development services of human gene based therapies | Health Technology |
Replimune Group, Inc.
 Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
Oxyrane, Ltd. | |
Replimune Ltd.
Replimune Ltd. Miscellaneous Commercial ServicesCommercial Services Research and develops cancer therapeutics | Commercial Services |
Forbion European Acquisition Corp.
 Forbion European Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
enGene Holdings, Inc.
 enGene Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biotechnology company that develops, manufactures and sells non-viral genetic medicines | Commercial Services |
- Stock Market
- Insiders
- Philip Astley-Sparke
